Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|June 14, 2021

A Welcome Addition to the Child and Adolescent ADHD Armamentarium

Author(s)Ann Childress, MD

This new medication is a huge leap forward for treating attention-deficit/hyperactivity disorder.

Ann Childress, MD, talks about Qelbree and the importance of its approval by the US Food and Drug Administration.

Dr Childress is a practicing psychiatrist with a subspecialty in child and adolescent psychiatry, clinical researcher, and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

andranik123/Adobe Stock

Morning Rounds: August 24-31

ByJessica Walters

August 31st 2026

Photographee.eu/Adobe Stock

Psyched Perspectives: Closing the ADHD Diagnostic Gap for Girls and Minority Youth

ByFrank A. Clark, MD,Paige Walton, MD

August 28th 2026

teen social media

An Update on the Harms of Social Media on Teen Mental Health: Meta Settles for $18 Billion

August 28th 2026

Butsarakham/Adobe Stock

Psyched Perspectives: ADHD in Underrecognized Populations, With Paige Walton, MD

ByFrank A. Clark, MD,Paige Walton, MD

August 19th 2026

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

ByHeidi Anne Duerr, MPH

August 12th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Ethics and AI Use in Medical Practice: American College of Physicians Releases Position Statement

Presenting Our September 2026 Theme: Depressive Disorders